Pasireotide monotherapy in Cushing's disease: a single-centre experience with 5-year extension of phase III Trial (Q33163578)

23 July 2017

Pasireotide monotherapy in Cushing's disease: a single-centre experience with 5-year extension of phase III Trial (English)

1 reference

23 July 2017

phase III clinical trial

0 references

1 reference

2

Isabelle Bourdeau

1 reference

23 July 2017

6

André Lacroix

1 reference

23 July 2017

Jessica MacKenzie Feder

1

1 reference

23 July 2017

Sophie Vallette

3

1 reference

23 July 2017

Hugues Beauregard

4

1 reference

23 July 2017

Louis-Georges Ste-Marie

5

1 reference

23 July 2017

1 December 2014

1 reference

23 July 2017

1 reference

23 July 2017

17

1 reference

23 July 2017

519-529

1 reference

23 July 2017

6

1 reference

https://scigraph.springernature.com/pub.10.1007/s11102-013-0539-4

23 July 2017

0 references

cites work

Mortality in Cushing's syndrome: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1007%2FS11102-013-0539-4

Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-013-0539-4

The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-013-0539-4

Cabergoline monotherapy in the long-term treatment of Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-013-0539-4

SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-013-0539-4

The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-013-0539-4

Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-013-0539-4

Beta-lipotropin and cortisol responses to an intravenous infusion dexamethasone suppression test in Cushing's syndrome and obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-013-0539-4

Extended treatment of Cushing's disease with pasireotide: results from a 2-year, Phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-013-0539-4

Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-013-0539-4

Pituitary-directed medical therapy with pasireotide for a corticotroph macroadenoma: pituitary volume reduction and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-013-0539-4

Sustained improvements in plasma ACTH and clinical status in a patient with Nelson's syndrome treated with pasireotide LAR, a multireceptor somatostatin analog.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-013-0539-4

Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-013-0539-4

Effects of somatostatin analogs on glucose homeostasis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-013-0539-4

An open-label dose-escalation study of once-daily and twice-daily pasireotide in healthy volunteers: safety, tolerability, and effects on glucose, insulin, and glucagon levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-013-0539-4

Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-013-0539-4

Withdrawal of somatostatin analogue therapy in patients with acromegaly is associated with an increased risk of acute biliary problems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-013-0539-4

Somatostatin analogs and gallstones: a retrospective survey on a large series of acromegalic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11102-013-0539-4

A 12-Month Phase 3 Study of Pasireotide in Cushing's Disease

21 January 2018

1 reference

12 December 2020

Transient efficacy of octreotide and pasireotide (SOM230) treatment in GIP-dependent Cushing's syndrome

1 reference

12 December 2020

Somatostatin-28 regulates GLP-1 secretion via somatostatin receptor subtype 5 in rat intestinal cultures

1 reference

12 December 2020

Pasireotide: a review of its use in Cushing's disease

1 reference

12 December 2020

Multiple once-daily subcutaneous doses of pasireotide were well tolerated in healthy male volunteers: a randomized, double-blind, placebo-controlled, cross-over, Phase I study

1 reference

12 December 2020

10.1007/S11102-013-0539-4

Identifiers

DOI

1 reference

23 July 2017

1 reference